WilmerHale Advises TRIANA Biomedicines on $120M Series B Financing

WilmerHale Advises TRIANA Biomedicines on $120M Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale advised TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, in the successful closing of its oversubscribed $120 million Series B financing round. The proceeds from the financing will support development of Triana’s lead product candidate TRI-611, an anaplastic lymphoma kinase–positive (ALK) targeted molecular glue degrader, to clinical proof of concept in ALK+ non-small cell lung cancer (NSCLC), selection of a second product candidate, and the advancement of TRIANA’s product pipeline beyond TRI-611. 

The WilmerHale team advising TRIANA was led by Stuart Falber and included Hilary Baker Jennings, Helen Park and Eugena Liu.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel